# Decalcification of the Aortic Valve by Vitamin K2 (Menaquinone-7)

Study · id `cardio:ct-nct03305536` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03305536](<https://clinicaltrials.gov/study/NCT03305536>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03305536

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

## Technical summary

Registry record NCT03305536. Randomized; quadruple masking; primary purpose treatment. Start 2018-01-02 (actual); primary completion 2020-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT03305536, source copy `cardio:ctgov-nct03305536-2019-08-09`, retrieved 2026-10-26)
- Started: 2018-01-02 (actual) (ClinicalTrials.gov record NCT03305536, source copy `cardio:ctgov-nct03305536-2019-08-09`, retrieved 2026-10-26)
- Primary completion: 2020-12 (anticipated) (ClinicalTrials.gov record NCT03305536, source copy `cardio:ctgov-nct03305536-2019-08-09`, retrieved 2026-10-26)
- Completion: 2020-12 (anticipated) (ClinicalTrials.gov record NCT03305536, source copy `cardio:ctgov-nct03305536-2019-08-09`, retrieved 2026-10-26)
- Countries: Lebanon (ClinicalTrials.gov record NCT03305536, source copy `cardio:ctgov-nct03305536-2019-08-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03305536-2019-08-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Decalcification of the Aortic Valve by Vitamin K2 (Menaquinone-7)
- Acronym: DECAV-K2
- Condition: Aortic Valve Disease
- Intervention (Dietary supplement): Vitamin K2 (Menaquinone 7) + Vitamin D3
- Lead sponsor: Hopital St. Georges, Ajaltoun
- Lead sponsor class: OTHER
- Collaborator: Omicron Pharmaceuticals
- Collaborator class: INDUSTRY
- Collaborator: Nattopharma ASA
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as a collaborator: Omicron Pharmaceuticals (`cardio:org-omicron-pharmaceuticals`)

## Provenance

Content hash: 9c1eee7c46ad5c1dcaca113f97848ba5716f7dfdd2ec1e611bea0751a1eaaf9f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
